FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912673050> ?p ?o ?g. }

• W2912673050 endingPage "362" @default.
• W2912673050 startingPage "362" @default.
• W2912673050 abstract "362 Background: Although FOLFIRINOX (5-Fluorouracil + leucovorin + irinotecan + oxaliplatin) is now the standard of care for patients (pts) with metastatic pancreatic cancer (PC) based on the 2011 study by Conroy et al. which demonstrated improved median overall survival (mOS) (11.1 vs 6.8 months [m] with gemcitabine, P < 0.001), pts > 75 yrs old were excluded from this study. As per SEER 2011-2015 data, 38% of new PC cases are diagnosed in pts age > 75. The purpose of this study was to assess the safety and efficacy of FOLFIRINOX in this group of pts. Methods: We retrospectively analyzed unresectable PC pts, age ≥ 75, treated with FOLFIRINOX at MD Anderson since 2011. Data obtained include demographics, line of treatment (tx), starting dose, progression free survival (PFS), OS and toxicities. Response was determined by chart documentation. Primary outcomes were mOS and rates of grade 3/4 hematologic toxicity (HT). Results: A total of 24 pts (19 male) were included with median age of 76 (range 75 to 84). 18 had metastatic disease, and FOLFIRINOX was the 1st line of tx for 18 of the 24 pts. The median number of cycles administered was 4 (range 1 to 12). The most frequent starting doses of infusional 5-FU, irinotecan and oxaliplatin were 2400, 150 and 75 mg/m 2 , respectively. Bolus 5-FU and leucovorin were omitted in all but 3 pts. Median PFS was 3.7 m (95% CI: 3.0-5.7) with mOS of 11.6 m (95% CI: 6.14-15.7). 16 pts (67%) experienced disease control (response to tx or stable disease). Grade 3 or 4 HT occurred in 11 pts (46%), and 9 (38%) were supported with granulocyte colony-stimulating factor at some point during tx. 6 pts (25%) required hospital admission for any toxicity, most commonly infection (3 pts), and 10 (42%) stopped FOLFIRINOX due to toxicity, most commonly fatigue (6 pts). Conclusions: In this single-center retrospective analysis of 24 unresectable PC pts age 75 or older given FOLFIRINOX, OS outcomes were similar to those reported by Conroy et al in the original trial which excluded pts older than 75. In our review, toxicities including incidences of grade 3 or 4 HT were similar to those reported in the initial study. These data indicate that the use of modified dosing FOLFIRINOX in advanced PC pts older than 75 appears to maintain similar efficacy and toxicity when compared to younger pts." @default.
• W2912673050 created "2019-02-21" @default.
• W2912673050 creator A5003827387 @default.
• W2912673050 creator A5004999918 @default.
• W2912673050 creator A5005194857 @default.
• W2912673050 creator A5012936802 @default.
• W2912673050 creator A5013187820 @default.
• W2912673050 creator A5032970786 @default.
• W2912673050 creator A5035371911 @default.
• W2912673050 creator A5062897162 @default.
• W2912673050 creator A5082224406 @default.
• W2912673050 creator A5084349853 @default.
• W2912673050 creator A5088853428 @default.
• W2912673050 date "2019-02-01" @default.
• W2912673050 modified "2023-09-24" @default.
• W2912673050 title "FOLFIRINOX in pancreatic cancer patients age 75 years or older." @default.
• W2912673050 doi "https://doi.org/10.1200/jco.2019.37.4_suppl.362" @default.
• W2912673050 hasPublicationYear "2019" @default.
• W2912673050 type Work @default.
• W2912673050 sameAs 2912673050 @default.
• W2912673050 citedByCount "2" @default.
• W2912673050 countsByYear W29126730502020 @default.
• W2912673050 countsByYear W29126730502021 @default.
• W2912673050 crossrefType "journal-article" @default.
• W2912673050 hasAuthorship W2912673050A5003827387 @default.
• W2912673050 hasAuthorship W2912673050A5004999918 @default.
• W2912673050 hasAuthorship W2912673050A5005194857 @default.
• W2912673050 hasAuthorship W2912673050A5012936802 @default.
• W2912673050 hasAuthorship W2912673050A5013187820 @default.
• W2912673050 hasAuthorship W2912673050A5032970786 @default.
• W2912673050 hasAuthorship W2912673050A5035371911 @default.
• W2912673050 hasAuthorship W2912673050A5062897162 @default.
• W2912673050 hasAuthorship W2912673050A5082224406 @default.
• W2912673050 hasAuthorship W2912673050A5084349853 @default.
• W2912673050 hasAuthorship W2912673050A5088853428 @default.
• W2912673050 hasConcept C121608353 @default.
• W2912673050 hasConcept C126322002 @default.
• W2912673050 hasConcept C141071460 @default.
• W2912673050 hasConcept C143998085 @default.
• W2912673050 hasConcept C2776694085 @default.
• W2912673050 hasConcept C2776907518 @default.
• W2912673050 hasConcept C2777063308 @default.
• W2912673050 hasConcept C2777148230 @default.
• W2912673050 hasConcept C2780210213 @default.
• W2912673050 hasConcept C2780258809 @default.
• W2912673050 hasConcept C2780259306 @default.
• W2912673050 hasConcept C2780456651 @default.
• W2912673050 hasConcept C2780739268 @default.
• W2912673050 hasConcept C2780962732 @default.
• W2912673050 hasConcept C29730261 @default.
• W2912673050 hasConcept C526805850 @default.
• W2912673050 hasConcept C71924100 @default.
• W2912673050 hasConcept C90924648 @default.
• W2912673050 hasConceptScore W2912673050C121608353 @default.
• W2912673050 hasConceptScore W2912673050C126322002 @default.
• W2912673050 hasConceptScore W2912673050C141071460 @default.
• W2912673050 hasConceptScore W2912673050C143998085 @default.
• W2912673050 hasConceptScore W2912673050C2776694085 @default.
• W2912673050 hasConceptScore W2912673050C2776907518 @default.
• W2912673050 hasConceptScore W2912673050C2777063308 @default.
• W2912673050 hasConceptScore W2912673050C2777148230 @default.
• W2912673050 hasConceptScore W2912673050C2780210213 @default.
• W2912673050 hasConceptScore W2912673050C2780258809 @default.
• W2912673050 hasConceptScore W2912673050C2780259306 @default.
• W2912673050 hasConceptScore W2912673050C2780456651 @default.
• W2912673050 hasConceptScore W2912673050C2780739268 @default.
• W2912673050 hasConceptScore W2912673050C2780962732 @default.
• W2912673050 hasConceptScore W2912673050C29730261 @default.
• W2912673050 hasConceptScore W2912673050C526805850 @default.
• W2912673050 hasConceptScore W2912673050C71924100 @default.
• W2912673050 hasConceptScore W2912673050C90924648 @default.
• W2912673050 hasIssue "4_suppl" @default.
• W2912673050 hasLocation W29126730501 @default.
• W2912673050 hasOpenAccess W2912673050 @default.
• W2912673050 hasPrimaryLocation W29126730501 @default.
• W2912673050 hasRelatedWork W1883975635 @default.
• W2912673050 hasRelatedWork W1974538215 @default.
• W2912673050 hasRelatedWork W2410090482 @default.
• W2912673050 hasRelatedWork W2476389627 @default.
• W2912673050 hasRelatedWork W2599910524 @default.
• W2912673050 hasRelatedWork W2910998150 @default.
• W2912673050 hasRelatedWork W3045328550 @default.
• W2912673050 hasRelatedWork W3092133951 @default.
• W2912673050 hasRelatedWork W3184807956 @default.
• W2912673050 hasRelatedWork W4380150473 @default.
• W2912673050 hasVolume "37" @default.
• W2912673050 isParatext "false" @default.
• W2912673050 isRetracted "false" @default.
• W2912673050 magId "2912673050" @default.
• W2912673050 workType "article" @default.